PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($2.66), $1.08 worse than the analyst estimate of ($1.58). Revenue for the quarter came in at $213.8 million versus the consensus estimate of $206.84 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.